相关实验视频

Updated: Jun 3, 2025

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

SATB2表达影响化疗代谢和免疫检查点结肠直肠癌中的基因表达

Barry Maguire¹, Batuhan Kisakol², Jochen H M Prehn²

¹Department of Colorectal Surgery, Beaumont Hospital, Dublin, Ireland; Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.

Clinical colorectal cancer

|January 10, 2025

概括

在结直肠癌 (CRC) 中,特殊的富含AT结合蛋白-2 (SATB2) 表达与更好的生存率有关,并影响化疗耐药性. 较低的SATB2与增加的免疫检查点基因表达相关,表明潜在的治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症基因组学癌症基因组学

背景情况:

特别的AT丰富结合蛋白-2 (SATB2) 是一种通常存在于结肠组织中的基因调节剂.
结直肠癌 (CRC) 中SATB2表达的减少与预后不佳和化疗耐药性有关.
SATB2可能会影响免疫检查点 (IC) 基因表达.

研究的目的:

研究SATB2表达与CRC临床病理特征之间的关联.
探索SATB2表达和与化疗耐药性和免疫检查点相关的基因之间的关系.

主要方法:

使用了癌症基因组图集PanCancer Atlas用于临床病理学和基因表达数据.
通过多变量回归分析,在不同患者组中比较SATB2表达.
分析了与化疗耐药性和免疫检查点基因表达的关联.

主要成果:

较低的SATB2表达与较差的疾病特异性存活率相关 (P = .04).
微卫星不稳定性 (MSI) 和粘膜瘤显示SATB2表达减少.
较低的SATB2与5-FU抗性基因和免疫检查点基因 (PD-1,PD-L1,TIM-3,CTLA-4) 的表达增加有关.

结论:

在CRC中,SATB2表达具有积极的预后影响,可能是通过降低5-FU抵抗.
在SATB2-低瘤中免疫检查点基因表达升高表明免疫治疗的潜力.
需要进一步的研究来探索在SATB2-低CRC病例中的免疫疗法.

关键词:

5 - - 甲酸是如何使用的在CMS1中,CMS1是CMS1.在PD-1中使用PD-1.在PD-L1中.预测预后预测预测

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...